TACROLIMUS
| Brand name | ENVARSUS XR |
|---|---|
| Active ingredient | TACROLIMUS |
| Strength | EQ 1MG BASE |
| Dosage form | TABLET, EXTENDED RELEASE |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | July 2015 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 8664239 | August 2028 | use U-2678 |
| 8685998 | August 2028 | product |
| 11123331 | May 2028 | use U-2677 |
| 11110081 | May 2028 | use U-2678 |
| 12083103 | May 2028 | use U-2678 |
| 10864199 | May 2028 | use U-2678 |
| 11419823 | May 2028 | product |
| 9549918 | May 2028 | product |
| 12403095 | May 2028 | product |
| 10166190 | May 2028 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.